Inotiv Inc (NOTV) - Total Liabilities

Latest as of March 2026: $625.32 Million USD

Based on the latest financial reports, Inotiv Inc (NOTV) has total liabilities worth $625.32 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Inotiv Inc - Total Liabilities Trend (1997–2025)

This chart illustrates how Inotiv Inc's total liabilities have evolved over time, based on quarterly financial data. See Inotiv Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Inotiv Inc Competitors by Total Liabilities

The table below lists competitors of Inotiv Inc ranked by their total liabilities.

Company Country Total Liabilities
MTI Investment SE
ST:MTI
Sweden Skr24.45 Million
Investment Friends Capital SE
WAR:IFC
Poland zł1.84 Million
Barakah Offshore Petroleum Bhd
KLSE:7251
Malaysia RM83.02 Million
Ridgetech, Inc.
NASDAQ:RDGT
USA $31.61 Million
Taylor Maritime Investments Limited
LSE:TMIP
UK GBX57.48 Million
TinOne Resources Inc
V:TORC
Canada CA$1.51 Million
DCM Financial Services Limited
NSE:DCMFINSERV
India Rs713.56 Million
American Rebel Holdings Inc
NASDAQ:AREB
USA $23.54 Million

Liability Composition Analysis (1997–2025)

This chart breaks down Inotiv Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Inotiv Inc.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.27 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 8.11 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.89 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Inotiv Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Inotiv Inc (1997–2025)

The table below shows the annual total liabilities of Inotiv Inc from 1997 to 2025.

Year Total Liabilities Change
2025-09-30 $635.09 Million +3.97%
2024-09-30 $610.86 Million +3.88%
2023-09-30 $588.04 Million -2.50%
2022-09-30 $603.13 Million +178.29%
2021-09-30 $216.73 Million +301.37%
2020-09-30 $54.00 Million +72.68%
2019-09-30 $31.27 Million +53.40%
2018-09-30 $20.38 Million +70.58%
2017-09-30 $11.95 Million -12.65%
2016-09-30 $13.68 Million +4.46%
2015-09-30 $13.10 Million -8.01%
2014-09-30 $14.24 Million -11.77%
2013-09-30 $16.14 Million -7.17%
2012-09-30 $17.39 Million +3.73%
2011-09-30 $16.76 Million -12.14%
2010-09-30 $19.08 Million -2.00%
2009-09-30 $19.46 Million -13.69%
2008-09-30 $22.55 Million -3.96%
2007-09-30 $23.48 Million -5.92%
2006-09-30 $24.96 Million -11.62%
2005-09-30 $28.24 Million +3.16%
2004-09-30 $27.38 Million +8.38%
2003-09-30 $25.26 Million +73.43%
2002-09-30 $14.56 Million +43.54%
2001-09-30 $10.15 Million -4.29%
2000-09-30 $10.60 Million +19.11%
1999-09-30 $8.90 Million +61.82%
1998-09-30 $5.50 Million -38.89%
1997-09-30 $9.00 Million --

About Inotiv Inc

NASDAQ:NOTV USA Diagnostics & Research
Market Cap
$1.26 Million
Market Cap Rank
#30359 Global
#6087 in USA
Share Price
$0.04
Change (1 day)
-28.00%
52-Week Range
$0.04 - $2.36
All Time High
$57.88
About

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences researc… Read more